| Toujeo® (Glargine U-300) |
Long-acting |
300 U/mL |
~6 h |
Flat |
Up to 36 h |
Once daily (same time) |
Smoother profile, ↓ nocturnal hypoglycemia vs Lantus; not unit-for-unit with Lantus. |
| Lantus® (Glargine U-100) |
Long-acting |
100 U/mL |
3–4 h |
Minimal |
~20–24 h |
Once daily |
Widely used; switching to/from Toujeo may need dose adjustment. |
| Levemir® (Detemir) |
Long-acting |
100 U/mL |
1–2 h |
Flat–slight |
~12–20 h |
Once or twice daily |
Duration shorter at low doses; weight-neutral effect. |
| Tresiba® (Degludec) |
Ultra-long acting |
100 U/mL, 200 U/mL |
1–2 h |
Flat |
>42 h |
Once daily (flexible timing, 8–40 h window) |
Longest duration; lowest hypoglycemia risk; useful if adherence is an issue. |
| NPH (Humulin N®, Novolin N®) |
Intermediate-acting |
100 U/mL |
2–4 h |
Pronounced peak (4–8 h) |
12–18 h |
Twice daily |
Higher hypoglycemia risk (esp. nocturnal); less expensive; used in pregnancy protocols. |
